Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.

Autor: Robbins DW; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Noviski MA; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Tan YS; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Konst ZA; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Kelly A; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Auger P; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Brathaban N; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Cass R; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Chan ML; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Cherala G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Clifton MC; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Gajewski S; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Ingallinera TG; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Karr D; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Kato D; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Ma J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., McKinnell J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., McIntosh J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Mihalic J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Murphy B; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Panga JR; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Peng G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Powers J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Perez L; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Rountree R; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Tenn-McClellan A; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Sands AT; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Weiss DR; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Wu J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Ye J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Guiducci C; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Hansen G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States., Cohen F; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2321-2336. Date of Electronic Publication: 2024 Feb 01.

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.

Autor: Pepin XJH; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom. Electronic address: xavier.pepin@astrazeneca.com., Moir AJ; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Mann JC; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Sanderson NJ; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Barker R; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Meehan E; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Plumb AP; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Bailey GR; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Murphy DS; AstraZeneca, Pharmaceutical Technology and Development, Charter Way, Macclesfield SK10 2NA, United Kingdom., Krejsa CM; Acerta Pharma, 121 Oyster Point Blvd, South San Francisco CA 94080, USA(1)., Andrew MA; Acerta Pharma, 121 Oyster Point Blvd, South San Francisco CA 94080, USA(1)., Ingallinera TG; Acerta Pharma, 121 Oyster Point Blvd, South San Francisco CA 94080, USA(1)., Slatter JG; Acerta Pharma, 121 Oyster Point Blvd, South San Francisco CA 94080, USA(1).

Publikováno v: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2019 Sep; Vol. 142, pp. 435-448. Date of Electronic Publication: 2019 Jul 12.